Abstract
Ischemic stroke is responsible for about one third of all deaths in industrialized countries and is the major cause of serious, long-term disability in adults over the age of 45. It stands to reason that there is a need for pharmacotherapy to treat acute ischemic stroke. In over two decades of research, the hope of developing a neuroprotective drug that effectively reduces the severity of damage after stroke has not been realized. However, considerable insights have been gained into the mechanisms and cascade of events that occurs following stroke as well as an improved understanding of neuronal injury and cell death. Recent studies in humans indicate many parallels with animal studies not only in the nature of events following ischemia, but also in their time course. Multiple pathways are known to be involved and yet the majority of treatments are still being designed to target a single effector in these pathways. Combinations of drugs, or drugs, which have multiple actions, targeting several pathways may prove to be a more successful strategy.
Keywords: stroke, neuroprotection, combination therapy, hybrid drugs, antioxidants, pharmacotherapy
Current Neuropharmacology
Title: Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants
Volume: 2 Issue: 3
Author(s): Jennifer K. Callaway
Affiliation:
Keywords: stroke, neuroprotection, combination therapy, hybrid drugs, antioxidants, pharmacotherapy
Abstract: Ischemic stroke is responsible for about one third of all deaths in industrialized countries and is the major cause of serious, long-term disability in adults over the age of 45. It stands to reason that there is a need for pharmacotherapy to treat acute ischemic stroke. In over two decades of research, the hope of developing a neuroprotective drug that effectively reduces the severity of damage after stroke has not been realized. However, considerable insights have been gained into the mechanisms and cascade of events that occurs following stroke as well as an improved understanding of neuronal injury and cell death. Recent studies in humans indicate many parallels with animal studies not only in the nature of events following ischemia, but also in their time course. Multiple pathways are known to be involved and yet the majority of treatments are still being designed to target a single effector in these pathways. Combinations of drugs, or drugs, which have multiple actions, targeting several pathways may prove to be a more successful strategy.
Export Options
About this article
Cite this article as:
Callaway K. Jennifer, Acute Stroke Therapy: Combination Drugs and Multifunctional Neuroprotectants, Current Neuropharmacology 2004; 2 (3) . https://dx.doi.org/10.2174/1570159043359602
DOI https://dx.doi.org/10.2174/1570159043359602 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Developmental Origins of Osteoporosis
Current Genomics Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Therapeutic Applications of Calcium Metabolism Modulation in Heart Disease
Medicinal Chemistry Association Between Heart Rate Variability and Parkinson’s Disease: A Meta-analysis
Current Pharmaceutical Design Peripheral Arterial Disease and Oxidative Stress
Vascular Disease Prevention (Discontinued) Soluble CD40L and its Role in Essential Hypertension: Diagnostic and Therapeutic Implications
Cardiovascular & Hematological Disorders-Drug Targets Association Between the Levels of Circulating Adhesion Molecules and Biopterins in Type-2 Diabetic Normotensive Patients Adhesion Molecules and Biopterins
Endocrine, Metabolic & Immune Disorders - Drug Targets Coronary Microcirculation in Ischemic Heart Disease
Current Pharmaceutical Design A Critical Approach of Guideline Therapeutic Recommendations for NAFLD
Current Vascular Pharmacology Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Plant Terpenes on Treating Cardiovascular and Metabolic Disease: A Review
Protein & Peptide Letters Antioxidant Effects of Natural Bioactive Compounds
Current Pharmaceutical Design Anthocyanins as a Potential Therapy for Diabetic Retinopathy
Current Medicinal Chemistry The State of the Problem of Achieving Extremely Low LDL Levels
Current Pharmaceutical Design Appropriate Application of Evidence to the Care of Elderly Patients with Diabetes
Current Diabetes Reviews Low-Density Lipoprotein Cholesterol (LDL-C): How Low?
Current Vascular Pharmacology Class IV Antiarrhythmic Agents: New Compounds Using an Old Strategy
Current Pharmaceutical Design Application of NMR Metabolomics to Search for Human Disease Biomarkers
Combinatorial Chemistry & High Throughput Screening Molecular Biological Roles of Ursolic Acid in the Treatment of Human Diseases
Current Bioactive Compounds Blood Atherogenicity as a Target for Anti-atherosclerotic Therapy
Current Pharmaceutical Design